Forlong Biotechnology, a synthetic immunology-driven protein drug developer based in Suzhou, has reportedly raised upwards of RMB 100 million (USD 14.74 million) in a Series A financing round. This significant capital injection will support the company’s ongoing efforts in research and development (R&D), pipeline filing and clinical trials, and business expansion.
Financing Details
The Series A round was led by Puhua Capital, with contributions from RenHe Capital, Fof Capital, Suzhou HIGH-TECH Venture Capital, Suzhou Hi-tech Innovation Angel Venture Capital, and Huangpu Healthcare Fund, alongside existing investor Co-Win Ventures. The proceeds will be used to accelerate Forlong Bio’s R&D activities, enhance its pipeline filing and clinical trials, and strengthen its business layout.
Forlong Bio’s Technology Platforms
Forlong Bio is known for its innovative technology platforms, including the F-body long-acting technology platform, synthetic new cytokine platform, Fc engineering platform, and biomolecular artificial evolution platform. These platforms have enabled the company to develop superior products, such as its lead pipeline FL115 (IL-15), which has demonstrated better pre-clinical safety and efficacy compared to similar products.-Fineline Info & Tech
